
- Media and Investors »
- Newsroom »
- Ad-hoc Releases »
- 2016
-
02/09/2016 15:11
PAION discontinues European Remimazolam Phase III Trial in cardiac surgery patients due to insufficient recruitment
-
02/18/2016 15:11
PAION reports about positive pre-NDA meeting with Japanese authority PMDA
-
04/11/2016 15:11
PAION successfully completes patient recruitment in Phase III study with Remimazolam for procedural sedation during colonoscopy
-
06/19/2016 15:11
PAION reports positive remimazolam headline data in pivotal U.S. Phase III study in procedural sedation for colonoscopy
-
06/24/2016 18:20
PAION grants Cosmo Pharmaceuticals Remimazolam license in the U.S. and Cosmo becomes largest Shareholder of PAION AG
-
12/19/2016 19:38
PAION successfully completes patient recruitment in U.S. clinical safety trial of remimazolam in high-risk patients undergoing colonoscopy